Chroman-2-one Compounds for DNA Damage Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current chemopreventive agents for lung cancer, such as (+)-Dihydromethysticin, have limited efficacy and are associated with side effects, necessitating the development of alternative compounds with fewer side effects that can effectively block tobacco carcinogen-induced DNA damage.
Innovation Solution
A compound of formula (I) is developed, which can be used to treat or prevent cancer by reducing DNA damage and protein damage, and detoxifying physical or chemical carcinogens, with specific structural features allowing for enhanced efficacy and reduced side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If (+)-Dihydromethysticin is used to block NNK-induced lung tumorigenesis, then DNA damage is reduced, but unwanted biological consequences occur due to aryl hydrocarbon receptor activation
Solution Approach 1:
The patent modifies the chemical structure of (+)-dihydromethysticin by changing substituents at positions R1, R2, and R7 to create compounds that maintain DNA protection activity while reducing aryl hydrocarbon receptor activation. Specific parameter changes include replacing hydrogen with hydroxy, halo, or trifluoromethyl groups, and forming fused ring structures, which alter the compound's biological profile to achieve selective inhibition of carcinogen-induced DNA damage without activating unwanted receptors.
Solution Approach 2:
The patent applies local quality modification by selectively changing specific positions in the molecular structure (R1, R2, R7 substituents) while maintaining the core chroman-2-one scaffold. This allows different regions of the molecule to have optimized properties: the core structure maintains DNA adduct prevention activity while the modified substituents reduce unwanted receptor activation, achieving localized functional optimization.
2Reliability
If chemopreventive agents are developed to block tobacco carcinogen-induced lung cancer, then cancer development is slowed, but side effects and moderate efficacy limit clinical application
Solution Approach 1:
The patent systematically varies chemical parameters (substituents at R1, R2, R7 positions) to optimize the efficacy-toxicity ratio. By exploring different combinations of hydroxy, halo, trifluoromethyl groups and fused ring structures, the patent identifies compounds with enhanced DNA protection activity and reduced side effects compared to the parent compound (+)-dihydromethysticin.
Solution Approach 2:
The patent creates composite molecular structures by combining the chroman-2-one core with various substituted groups and fused rings, resulting in a series of compound analogs with differentiated biological activities. This composite approach allows selection of specific analogs that exhibit superior chemopreventive efficacy with improved safety profiles.
Data Source
AI summary
The invention provides compounds that are useful for treating or preventing cancer.